ERBB receptor-regulated G1/S transition

Taxon: Human
Process: Cell cycle
Submitter: C. Chaouiya

Supporting paper: Sahin, Özgür and Fröhlich, Holger and Löbke, Christian and Korf, Ulrike and Burmester, Sara and Majety, Meher and Mattern, Jens and Schupp, Ingo and Chaouiya, Claudine and Thieffry, Denis and Poustka, Annemarie and Wiemann, Stefan and Beissbarth, Tim and Arlt, Dorit (2009). Modeling ERBB receptor-regulated G1/S transition to find novel targets for de novo trastuzumab resistance. BMC Systems Biology. 10.1186/1752-0509-3-1

Model file(s)	Description(s)
ErbB2_model.zginml	ERB2 model
AdditionalFile.pdf	Table encompassing the stable states and pRB response for single and multiple knockdowns of network proteins

Summary:
In breast cancer, overexpression of the transmembrane tyrosine kinase ERBB2 is an adverse prognostic marker, and occurs in almost 30% of the patients. For therapeutic intervention, ERBB2 is targeted by monoclonal antibody trastuzumab in adjuvant settings; however, de novo resistance to this antibody is still a serious issue, requiring the identification of additional targets to overcome resistance. In this study, we have combined computational simulations, experimental testing of simulation results, and finally reverse engineering of a protein interaction network to define potential therapeutic strategies for de novo trastuzumab resistant breast cancer.

First, we employed Boolean logic to model regulatory interactions and simulated single and multiple protein loss-of-functions. Then, our simulation results were tested experimentally by producing single and double knockdowns of the network components and measuring their effects on G1/S transition during cell cycle progression. Combinatorial targeting of ERBB2 and EGFR did not affect the response to trastuzumab in de novo resistant cells, which might be due to decoupling of receptor activation and cell cycle progression. Furthermore, examination of c-MYC in resistant as well as in sensitive cell lines, using a specific chemical inhibitor of c-MYC (alone or in combination with trastuzumab ), demonstrated that both trastuzumab sensitive and resistant cells responded to c-MYC perturbation.

In this study, we connected ERBB signaling with G1/S transition of the cell cycle via two major cell signaling pathways and two key transcription factors, to model an interaction network that allows for the identification of novel targets in the treatment of trastuzumab resistant breast cancer. Applying this new strategy, we found that, in contrast to trastuzumab sensitive breast cancer cells, combinatorial targeting of ERBB receptors or of key signaling intermediates does not have potential for treatment of de novo trastuzumab resistant cells. Instead, c-MYC was identified as a novel potential target protein in breast cancer cells.